Premium
National Cancer Institute Formulary: A Public‐Private Partnership Providing Investigators Access to Investigational Anticancer Agents
Author(s) -
Cristofaro JV,
Ansher SS,
Zwiebel JA,
Ivy P,
Conley B,
Abrams JS,
Doroshow JH
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.585
Subject(s) - formulary , general partnership , medicine , investigational drugs , cancer drugs , family medicine , pharmacology , drug , business , clinical trial , finance
As part of the White House Cancer Moonshot Initiative, the National Cancer Institute (NCI) has developed a drug formulary to provide investigational anticancer agents to the extramural research community. This article describes how the NCI Formulary functions, how researchers may apply for access to drugs in the formulary, and the NCI's initial goals for formulary participation. Approved investigators may apply for access to formulary agents at: https://nciformulary.cancer.gov.